Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

2021340 citationsJournal Articlebronze Open Access

Authors

Funda Meric‐Bernstam · The University of Texas MD Anderson Cancer Center

Randy F. Sweis · University of Chicago

F. Stephen Hodi · Dana-Farber Cancer Institute

Wells A. Messersmith · University of Colorado Cancer Center

Robert H.I. Andtbacka · Huntsman Cancer Institute

Matthew Ingham · Columbia University Irving Medical Center

Nancy Lewis

Abstract

MIW815 was well tolerated in patients with advanced/metastatic cancers. Clinical activity of single-agent MIW815 was limited in this first-in-human study; however, evidence of systemic immune activation was seen.

Topics & Keywords

interferon and immune responses RNA modifications and cancer NF-κB Signaling Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 28, Issue 4, pp. 677-688

DOI: 10.1158/1078-0432.ccr-21-1963

Field-Weighted Citation Impact: 16.13